We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

48 hedge funds and large institutions have $4.21M invested in Biotech Acquisition Company Warrant in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

8% less funds holding

Funds holding: 5248 (-4)

17% less capital invested

Capital invested by funds: $5.06M → $4.21M (-$846K)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
48
Holders Change
-4
Holders Change %
-7.69%
% of All Funds
0.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
10
Reduced
4
Closed
9
Calls
$5.72M
Puts
Net Calls
+$5.72M
Net Calls Change
-$26K

BIOTW Hedge Fund Activity: Q2 2022 in Review

48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q2 2022, worth a combined $4.21M — down 17% from $5.06M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BIOTW and 5 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 10 added.

The largest buyer was HGC Investment Management, adding an estimated $254K. The largest seller was Aristeia Capital, cutting an estimated $94.8K.

  • 48 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q2 2022, down from 52 in Q1 2022.
  • Funds reported $4.21M of Biotech Acquisition Company Warrant stock for Q2 2022, down 17% quarter-over-quarter.
  • 5 funds opened new Biotech Acquisition Company Warrant positions in Q2 2022 and 9 closed out, a net change of -4 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q2 2022 was HGC Investment Management, an estimated $254K added.
  • The largest Biotech Acquisition Company Warrant seller in Q2 2022 was Aristeia Capital, an estimated $94.8K sold.

Based on aggregated 13F filings for Q2 2022.